The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Lung Cancer—Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment
Abstract
Lung cancer remains the commonest cause of cancer death in both men and women in the developed world, although mortality rates for men are dropping. Spiral computed tomography (CT) of the chest in middle-aged, smoking subjects may identify two to four times more lung cancers than a chest X-ray, with more than 70% of tumors being Stage I. The incidence of benign nodules is high, making interpretation difficult. Randomized controlled trials are required to determine whether spiral CT detects lung cancer early enough to improve mortality. Preoperative staging has relied on CT scans, but positron emission tomography scanning has greater sensitivity, specificity, and accuracy than CT and is recommended as the final confirmatory investigation when the CT shows resectable disease. In locally advanced non-small cell lung cancer, there is a small advantage for the addition of chemotherapy to radiotherapy, but no advantage for postoperative radiotherapy. Chemotherapy gives no benefit when given as neoadjuvant or adjuvant treatment around surgery. In advanced disease, newer cytotoxic agents confer a small survival advantage over older combinations, but the advantage in median survival over best supportive care remains a few months with modest improvements in quality of life. Survival with small cell lung cancer has shown little increase over the last 15 years despite multiple attempts to manipulate the timing, dose intensity of chemotherapy, and the potential of radiotherapy. Novel therapies are urgently needed for all cell types of lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Smoking and Carcinoma of the Lung
Doll, R., & Hill, A. B. (1950) · BMJ · doi:10.1136/bmj.2.4682.739 · Cited by 1,999
Maintenance chemotherapy for small cell lung cancer: a critical review of the literature
Sculier, J. P., Berghmans, T., Castaigne, C., Luce, S., Sotiriou, C., Vermylen, P., & Paesmans, M. (1998) · Lung Cancer · doi:10.1016/s0169-5002(97)00084-6 · Cited by 92
Declining Lung Cancer Rates Among Young Men and Women in the United States: A Cohort Analysis
Devesa, S. S., Blot, W. J., & Fraumeni, J. F. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.20.1568 · Cited by 86
Cited by
Noninvasive Staging of Non-small Cell Lung Cancer*
Toloza, E. M., Harpole, L., & McCrory, D. C. (2003) · Chest · doi:10.1378/chest.123.1_suppl.137s · Cited by 745
Noninvasive Staging of Non-small Cell Lung Cancer
Silvestri, G. A., Gould, M. K., Margolis, M. L., Tanoue, L. T., McCrory, D., Toloza, E., & Detterbeck, F. (2007) · Chest · doi:10.1378/chest.07-1360 · Cited by 622
Endobronchial ultrasound guided transbronchial needle aspiration for staging of lung cancer
Yasufuku, K., Chiyo, M., Koh, E., Moriya, Y., Iyoda, A., Sekine, Y., Shibuya, K., Iizasa, T., & Fujisawa, T. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.07.013 · Cited by 483
Mangal, S., Gao, W., Li, T., & Zhou, Q. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.34 · Cited by 288
Johnson, A. M., Hines, R. B., Johnson, J. A., & Bayakly, A. R. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.01.008 · Cited by 145
Metadata
- Authors
- Spiro, S. G., & Porter, J. C.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-11-01
- Volume
- 166
- Issue
- 9
- Pages
- 1166-1196
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2152392221
- Cited by
- 249
- References
- 5
- FWCI
- 12.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lung Cancer—Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment. https://app.cochat.ai/papers/10.1164/rccm.200202-070so
- The paper
- Spiro, S. G., & Porter, J. C. (2002). Lung Cancer—Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.200202-070so
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.